Recently, the Department of Science & Technology of Shandong Province announced the results of the 2023 Shandong Natural Science Foundation Innovation and Development Joint Fund. A project titled "Research on Therapeutic Resistance Mechanisms in Colorectal Cancer Based on Organoid Microenvironment Interaction Models and Discovery of Key Biomarkers," jointly applied for by bioGenous BIOTECH, Inc. (hereinafter referred to as bioGenous) and Cancer Hospital of Shandong Medical University, has been approved for funding.
Colorectal cancer is a highly prevalent tumor among the Chinese population, and the main reasons for its clinical difficulty in treatment are therapeutic resistance and the lack of therapeutic targets. Aligning with the guidelines and objectives, this project builds on previously developed organoid technology and an established organoid bank for the digestive system to construct novel organoid models that can simulate the tumor microenvironment. It will investigate the role of the tumor microenvironment in therapeutic resistance, immune evasion, and tumor evolution. Through multi-omics analysis, high-throughput drug screening, and multi-dimensional organoid phenotype analysis methods, the project will conduct large-scale drug evaluations of commonly used clinical drugs for colorectal cancer and candidate drugs within the antitumor drug library. This will lay the foundation for early molecular diagnosis, precision treatment, target discovery, and drug development in colorectal cancer.
Shandong Natural Science Foundation Innovation and Development Joint Fund
The Shandong Natural Science Innovation and Development Joint Fund is a component of the Shandong Natural Science Fund. Such projects aim to leverage the guiding role of the Shandong Natural Science Fund, guide and integrate social resources into basic research, facilitate cooperation among relevant departments, enterprises, regions, universities, and scientific research institutions, cultivate scientific and technological talents, and promote the enhancement of independent innovation capabilities in relevant fields, industries, and regions within the province.
About bioGenous
bioGenous is a leading one-stop supplier of organoid technology products and solutions in China, dedicated to providing standardized and modular organoid products and technical support for biomedical scientific research, drug development, and clinical precision medicine. We possess internationally advanced organoid technology with independent intellectual property rights, covering multiple tissues and tumor organoid cultivation, gene manipulation, developmental and disease modeling, drug sensitivity and toxicity assessment, immune co-culture, organoid atlases, and spatial pathology. Our scientific team has deeply engaged in the standardization of organoid technology, aiming to lead the application of organoid models in multiple fields of biomedical science. We have already served over 200 new drug development enterprises, tertiary hospitals, and scientific research institutions. Our research team gathers a group of outstanding talents who have long been engaged in organoid research, intestinal homeostasis maintenance, colorectal cancer pathogenesis, multi-omics analysis, and big data in sample repositories, including one 973 Program Principal Investigator, one National Excellent Young Scientist, one recipient of the National Postdoctoral Innovative Talent Support Program, and one recipient of the National Postdoctoral International Exchange Program. Taking the establishment of this project as an opportunity, we will carefully summarize our experiences, plan ahead, focus on the frontier areas of organoid development, and fulfill our corporate mission of "Landscape of human organoids, Ideal model in clinics and research".
